Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. SUPPLEMENTARY INFORMATI...

Descripción completa

Detalles Bibliográficos
Autores principales: Vu, Tuan, Meisel, Andreas, Mantegazza, Renato, Annane, Djillali, Katsuno, Masahisa, Aguzzi, Rasha, Enayetallah, Ahmed, Beasley, Kathleen N., Rampal, Nishi, Howard, James F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Summary of Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444731/
https://www.ncbi.nlm.nih.gov/pubmed/37351816
http://dx.doi.org/10.1007/s40120-023-00514-4
_version_ 1785094014074093568
author Vu, Tuan
Meisel, Andreas
Mantegazza, Renato
Annane, Djillali
Katsuno, Masahisa
Aguzzi, Rasha
Enayetallah, Ahmed
Beasley, Kathleen N.
Rampal, Nishi
Howard, James F.
author_facet Vu, Tuan
Meisel, Andreas
Mantegazza, Renato
Annane, Djillali
Katsuno, Masahisa
Aguzzi, Rasha
Enayetallah, Ahmed
Beasley, Kathleen N.
Rampal, Nishi
Howard, James F.
author_sort Vu, Tuan
collection PubMed
description This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00514-4.
format Online
Article
Text
id pubmed-10444731
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-104447312023-08-24 Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis Vu, Tuan Meisel, Andreas Mantegazza, Renato Annane, Djillali Katsuno, Masahisa Aguzzi, Rasha Enayetallah, Ahmed Beasley, Kathleen N. Rampal, Nishi Howard, James F. Neurol Ther Summary of Research This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the drug ravulizumab in the rare disease, myasthenia gravis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40120-023-00514-4. Springer Healthcare 2023-06-23 /pmc/articles/PMC10444731/ /pubmed/37351816 http://dx.doi.org/10.1007/s40120-023-00514-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Summary of Research
Vu, Tuan
Meisel, Andreas
Mantegazza, Renato
Annane, Djillali
Katsuno, Masahisa
Aguzzi, Rasha
Enayetallah, Ahmed
Beasley, Kathleen N.
Rampal, Nishi
Howard, James F.
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
title Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
title_full Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
title_fullStr Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
title_full_unstemmed Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
title_short Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
title_sort summary of research: terminal complement inhibitor ravulizumab in generalized myasthenia gravis
topic Summary of Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444731/
https://www.ncbi.nlm.nih.gov/pubmed/37351816
http://dx.doi.org/10.1007/s40120-023-00514-4
work_keys_str_mv AT vutuan summaryofresearchterminalcomplementinhibitorravulizumabingeneralizedmyastheniagravis
AT meiselandreas summaryofresearchterminalcomplementinhibitorravulizumabingeneralizedmyastheniagravis
AT mantegazzarenato summaryofresearchterminalcomplementinhibitorravulizumabingeneralizedmyastheniagravis
AT annanedjillali summaryofresearchterminalcomplementinhibitorravulizumabingeneralizedmyastheniagravis
AT katsunomasahisa summaryofresearchterminalcomplementinhibitorravulizumabingeneralizedmyastheniagravis
AT aguzzirasha summaryofresearchterminalcomplementinhibitorravulizumabingeneralizedmyastheniagravis
AT enayetallahahmed summaryofresearchterminalcomplementinhibitorravulizumabingeneralizedmyastheniagravis
AT beasleykathleenn summaryofresearchterminalcomplementinhibitorravulizumabingeneralizedmyastheniagravis
AT rampalnishi summaryofresearchterminalcomplementinhibitorravulizumabingeneralizedmyastheniagravis
AT howardjamesf summaryofresearchterminalcomplementinhibitorravulizumabingeneralizedmyastheniagravis

Ejemplares similares